세계의 의료 진단 분야 인공지능(AI) 시장 : 구성요소별, 최종 사용자별, 양식별, 용도별, 지역별 - 2029년까지 예측

The global AI in medical diagnostics market is projected to reach USD 4.72 Billion by 2029 from USD 1.71 Billion in 2024, at a CAGR of 22.5% during the forecast period. The adoption of AI in medical diagnostics is rising at a faster pace owing to factors such as growing government focus on increasing uptake of AI-based technologies, AI solutions being more used by radiologists to decrease workload, and the increasing number of cross-industry partnerships & collaborations.

However, the shortage of trained AI workforce and unstable regulations are factors expected to restrain the market growth.

"Services segment is expected to grow at the highest rate from 2024 to 2029 in global AI in medical diagnostics market"

The AI in medical diagnostics market is categorized by components into software, hardware, and services. In 2023, the software segment dominated the market due to its capability to streamline operations, automate workflows, and enhance diagnostic accuracy. However, from 2024 to 2029, the services segment is expected to witness the highest growth rate, driven by increasing demand for managed services, integration support, and training required to deploy and optimize AI solutions in healthcare settings. These services help address challenges such as limited healthcare staff and the growing volume of imaging scans, enabling healthcare providers to achieve operational efficiency and improved patient care.

"In Vivo Diagnostics Segment is estimated to account for the largest share of the global AI in medical diagnostics market in 2023"

The AI in the medical diagnostics market is also segmented by application into in vivo and in vitro diagnostics. In 2023, the in vivo diagnostics segment is anticipated to hold the largest market share due to the growing adoption of AI solutions by healthcare practitioners. These solutions assist in real-time imaging analysis, reducing human error, and improving treatment outcomes. In vivo diagnostics applications, such as AI-powered imaging for cancer detection and cardiovascular assessments, are widely used in clinical practice. While the in vivo segment leads currently, the in vitro segment, focusing on AI-based tools for laboratory testing and analysis, is expected to exhibit vigorous growth during the forecast period, driven by growing advancements in AI for precision diagnostics and laboratory automation.

"The Hospitals segment is estimated to account for the largest share of the global AI in medical diagnostics market in 2023"

By end users, the AI in the medical diagnostics market is divided into hospitals, diagnostic imaging centers, diagnostic laboratories, and other end users. In 2023, the hospital segment is projected to hold the largest market share of this market. Factors such as the increase in the adoption of MIS procedures in hospitals to enhance the quality of patient care, and the advancement in the application of imaging modalities to improve workflow.

"North America to dominate the AI in medical diagnostics market in 2023."

Geographically, the AI in medical diagnostics market can be broadly categorized into five key regional segments: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The region of North America is likely to see the maximum share in 2023, due to advanced health care infrastructure, with widespread adoption of AI technologies and significant investment in R&D by companies and institutions. However, the Asia-Pacific region is forecasted to grow with the highest CAGR over the period from 2024-2029, due to a growing prevalence of cancer, increased use of AI in diagnostics and for the purpose of health system upgradation by the government.

Breakdown of supply-side primary interviews, by company type, designation, and region:

• By Company Type: Tier 1 (35%), Tier 2 (45%), and Tier 3 (20%)
• By Designation: C-level (35%), Director-level (25%), and Others (40%)
• By Region: North America (40%), Europe (30%), Asia Pacific (20%), and RoW (10%)

The prominent players in this market are Microsoft (US), Merative (US), Intel Corporation (US), NVIDIA Corporation (US), Google (US), GE HealthCare (US), Digital Diagnostics Inc. (US), Siemens Healthineers (Germany), Koninklijke Philips N.V. (Netherlands), Advanced Micro Devices, Inc. (US), HeartFlow, Inc. (US), Enlitic, Inc. (US), InformAI (US), isometric (Belgium), Butterfly Network, Inc. (US), Aidence (Netherlands), Nano-X Imaging LTD. (Israel), Quibim (Spain), Qure.ai (India), Viz.ai, Inc (US), Aidoc (US), Lunit, Inc. (South Korea), Therapixel (France), EchoNous, Inc. (US), and Brainomix (UK).

• Research Coverage
• The report studies the AI in medical diagnostics market based on component, application, end user, modality and region
• The report analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth
• The report evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders
• The report studies micro-markets with respect to their growth trends, prospects, and contributions to the total AI in medical diagnostics market
• The report forecasts the revenue of market segments with respect to five major regions

Rationale to Buy the Report

The research report will help smaller and newer businesses as well as established ones understand the state of the market, which will help them increase their market share. Businesses that purchase the study may choose to employ one or more of the tactics listed below to increase their market presence.

This report provides insightful data on the following pointers:

• Analysis of key drivers (Influx of big data, a growing number of cross-industry partnerships, increasing adoption of AI solutions to reduce work pressure on radiologists, rising government initiatives), restraints (Reluctance among medical practitioners to adopt AI-based technologies, Inadequate AI workforce and ambiguous regulatory guidelines for medical software), opportunities (Untapped emerging markets, Increasing focus on developing human-aware AI systems), and challenges (Budgetary constraints, Unstructured healthcare data) influencing the growth of the ai in medical diagnostics market
• Market Penetration: In-depth coverage of product portfolios offered by the top players in the AI in the medical diagnstics market.
• Product Development/Innovation: In-depth coverage of product portfolios offered by the top players in the AI in the medical diagnstics market.
• Market Development: Insightful data on profitable developing areas.
• Market Diversification: Details about recent developments and advancements in the AI in the medical diagnstics market.
• Competitive Assessment: Extensive assessment of the products, growth tactics, revenue projections, and market categories of the top competitors.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKETS COVERED AND REGIONAL SCOPE
  • 1.3.2 INCLUSIONS AND EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 LIMITATIONS
  • 1.4.1 SCOPE-RELATED LIMITATIONS
  • 1.4.2 METHODOLOGY-RELATED LIMITATIONS
• 1.5 STAKEHOLDERS
• 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 List of secondary sources
    • 2.1.1.2 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 List of primary sources
    • 2.1.2.2 Key data from primary sources
    • 2.1.2.3 Key industry insights
    • 2.1.2.4 Breakdown of interviews with experts
• 2.2 MARKET SIZE ESTIMATION
• 2.3 FACTOR ANALYSIS
• 2.4 GROWTH FORECAST
• 2.5 DATA TRIANGULATION
• 2.6 RESEARCH ASSUMPTIONS
• 2.7 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN ARTIFICIAL INTELLIGENCE IN MEDICAL DIAGNOSTICS MARKET
• 4.2 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN MEDICAL DIAGNOSTICS MARKET, BY APPLICATION AND COUNTRY
• 4.3 ARTIFICIAL INTELLIGENCE IN MEDICAL DIAGNOSTICS MARKET, BY KEY COUNTRY
• 4.4 ARTIFICIAL INTELLIGENCE IN MEDICAL DIAGNOSTICS MARKET, BY REGION
• 4.5 ARTIFICIAL INTELLIGENCE IN MEDICAL DIAGNOSTICS MARKET: DEVELOPED VS. EMERGING ECONOMIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Influx of big data with increasing digitization and adoption of information systems
    • 5.2.1.2 Surge in cross-industry partnerships & collaborations
    • 5.2.1.3 Increasing demand for AI-based solutions in radiology
    • 5.2.1.4 Rising government initiatives to implement AI-based technologies in healthcare settings
    • 5.2.1.5 Availability of extensive funding for AI-based startups
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Reluctance among medical practitioners to adopt AI-based technologies
    • 5.2.2.2 Inadequate AI workforce and ambiguous regulatory guidelines for medical software
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Untapped emerging markets
    • 5.2.3.2 Increasing focus on developing human-aware AI systems
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Budgetary constraints
    • 5.2.4.2 Unstructured healthcare data due to growing digital footprint and technology trends
    • 5.2.4.3 Privacy concerns related to data protection
    • 5.2.4.4 Limited interoperability for AI solutions
• 5.3 ECOSYSTEM ANALYSIS
• 5.4 CASE STUDY ANALYSIS
  • 5.4.1 MAYO CLINIC INTEGRATES AI-ENABLED DIGITAL DIAGNOSTICS AND BOOSTS MEDICAL RESEARCH WITH GOOGLE CLOUD PLATFORM
  • 5.4.2 RESOLVING CHALLENGES OF UNDERSTAFFED WORKFORCE AND BACKLOG WITH VEYE LUNG NODULES
  • 5.4.3 NVIDIA AI ENTERPRISE SOFTWARE AND GPUS HELP IMPROVE PERFORMANCE AND PRECISION OF TUMOR TARGETING
  • 5.4.4 ZHEJIANG UNIVERSITY AND ZHEJIANG DE IMAGE SOLUTIONS USE INTEL AI SOLUTIONS TO PROCESS ULTRASOUND
  • 5.4.5 WAITEMATA DISTRICT HEALTH BOARD PROJECT UTILIZES PRECISION-DRIVEN HEALTH SOLUTIONS
• 5.5 VALUE CHAIN ANALYSIS
  • 5.5.1 UPSTREAM
  • 5.5.2 MID-STREAM
  • 5.5.3 DOWNSTREAM
• 5.6 TRADE ANALYSIS
• 5.7 PORTER'S FIVE FORCES ANALYSIS
  • 5.7.1 THREAT OF NEW ENTRANTS
  • 5.7.2 THREAT OF SUBSTITUTES
  • 5.7.3 BARGAINING POWER OF SUPPLIERS
  • 5.7.4 BARGAINING POWER OF BUYERS
  • 5.7.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.8 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.8.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.8.2 BUYING CRITERIA
• 5.9 REGULATORY LANDSCAPE
  • 5.9.1 NORTH AMERICA
    • 5.9.1.1 Health Insurance Portability and Accountability Act of 1996 (HIPAA)
    • 5.9.1.2 Health Information Technology for Economic and Clinical Health Act of 2009 (HITECH)
    • 5.9.1.3 Consumer Privacy Protection Act of 2017
    • 5.9.1.4 National Cybersecurity Protection Advancement Act of 2015
    • 5.9.1.5 Future of Life Institute's Asilomar AI Principles
  • 5.9.2 EUROPE
    • 5.9.2.1 European Medical Devices Regulation (EU) 2017/745 and In-vitro Diagnostic Medical Devices Regulation (EU) 2017/746, in Combination with General Data Protection Regulation 2016/679
    • 5.9.2.2 Artificial Intelligence Act (AI Act)
  • 5.9.3 ASIA PACIFIC
    • 5.9.3.1 Cybersecurity Law of the People's Republic of China
  • 5.9.4 REST OF WORLD
    • 5.9.4.1 Protection of Personal Information Act
  • 5.9.5 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.10 PATENT ANALYSIS
  • 5.10.1 PATENT PUBLICATION TRENDS FOR AI IN MEDICAL DIAGNOSTICS
  • 5.10.2 JURISDICTION AND TOP APPLICANT ANALYSIS
• 5.11 TECHNOLOGY ANALYSIS
  • 5.11.1 KEY TECHNOLOGIES
    • 5.11.1.1 Machine learning
    • 5.11.1.2 Deep learning
  • 5.11.2 COMPLEMENTARY TECHNOLOGIES
    • 5.11.2.1 Laboratory automation
    • 5.11.2.2 EHR
  • 5.11.3 ADJACENT TECHNOLOGIES
    • 5.11.3.1 Natural language processing
    • 5.11.3.2 Big data analytics
• 5.12 PRICING ANALYSIS
  • 5.12.1 INDICATIVE PRICING ANALYSIS, BY COMPONENT
  • 5.12.2 INDICATIVE PRICING ANALYSIS OF KEY PLAYERS, BY COMPONENT
  • 5.12.3 INDICATIVE PRICING ANALYSIS, BY REGION
• 5.13 KEY CONFERENCES & EVENTS, 2024-2025
• 5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
• 5.15 UNMET NEEDS: ARTIFICIAL INTELLIGENCE IN MEDICAL DIAGNOSTICS MARKET
  • 5.15.1 END USER EXPECTATIONS
• 5.16 REIMBURSEMENT SCENARIO
  • 5.16.1 REIMBURSEMENT FOR AI SOFTWARE IN RADIOLOGY
• 5.17 INVESTMENT AND FUNDING SCENARIO

6 ARTIFICIAL INTELLIGENCE IN MEDICAL DIAGNOSTICS MARKET, BY COMPONENT

• 6.1 INTRODUCTION
• 6.2 SOFTWARE
  • 6.2.1 IMAGING SOFTWARE
    • 6.2.1.1 Integration of advanced features (3D rendering, AI-driven image analysis, and automated reporting) to drive demand
  • 6.2.2 PREDICTIVE ANALYSIS SOFTWARE
    • 6.2.2.1 Growing use of AI-powered predictive analytics in healthcare for early disease detection, personalized treatment, and enhancing operational efficiency to drive market
  • 6.2.3 DIAGNOSTIC SOFTWARE
    • 6.2.3.1 Increased integration of AI into diagnostic processes for enhancing accuracy and efficiency to fuel market growth
• 6.3 SERVICES
  • 6.3.1 RISING DEPLOYMENT AND INTEGRATION OF AI SYSTEMS TO DRIVE DEMAND
• 6.4 HARDWARE
  • 6.4.1 PROCESSORS
    • 6.4.1.1 MPU
      • 6.4.1.1.1 Increasing demand for AI-powered medical diagnostic systems for accurate imaging in radiology, oncology, and cardiology to drive market
    • 6.4.1.2 GPU
      • 6.4.1.2.1 Ability to enhance accuracy and efficacy of medical imaging and diagnostics to drive demand
    • 6.4.1.3 FPGA
      • 6.4.1.3.1 Capability to optimize speed and accuracy of medical image processing and improve robustness of medical imaging systems to drive demand
    • 6.4.1.4 ASIC
      • 6.4.1.4.1 Rapid operation feature to support demand
  • 6.4.2 MEMORY
    • 6.4.2.1 Development of high-bandwidth memory for AI applications to drive market
  • 6.4.3 NETWORKS
    • 6.4.3.1 Adapter
      • 6.4.3.1.1 Increasing demand for seamless data integration and growing adoption of machine learning and imaging technologies to drive market
    • 6.4.3.2 Switch
      • 6.4.3.2.1 Efficient data routing and integration features to fuel demand
    • 6.4.3.3 Interconnect
      • 6.4.3.3.1 Need for efficient data transmission to drive demand

7 ARTIFICIAL INTELLIGENCE IN MEDICAL DIAGNOSTICS MARKET, BY END USER

• 7.1 INTRODUCTION
• 7.2 HOSPITALS
  • 7.2.1 RISING INSTALLATION OF ADVANCED AI DIAGNOSTIC IMAGING SOLUTIONS TO DRIVE MARKET
• 7.3 DIAGNOSTIC IMAGING CENTERS
  • 7.3.1 INCREASING NUMBER OF PRIVATE IMAGING CENTERS TO DRIVE MARKET
• 7.4 DIAGNOSTIC LABORATORIES
  • 7.4.1 RISING SPECIMEN TEST VOLUMES TO DRIVE MARKET
• 7.5 OTHER END USERS

8 ARTIFICIAL INTELLIGENCE IN MEDICAL DIAGNOSTICS MARKET, BY MODALITY

• 8.1 INTRODUCTION
• 8.2 IMAGING MODALITIES
  • 8.2.1 COMPUTED TOMOGRAPHY
    • 8.2.1.1 Rising availability of cardiac CT devices enabled with AI solutions to drive market
  • 8.2.2 X-RAY
    • 8.2.2.1 Innovative AI solutions for x-ray imaging by key players to drive market
  • 8.2.3 MAGNETIC RESONANCE IMAGING
    • 8.2.3.1 Rising technological advancements to drive adoption of AI in MRI
  • 8.2.4 ULTRASOUND
    • 8.2.4.1 Increasing prevalence of ovarian cancer to drive market
  • 8.2.5 MAMMOGRAPHY
    • 8.2.5.1 Increasing prevalence of breast cancer to drive market
  • 8.2.6 OTHER IMAGING MODALITIES
• 8.3 DIAGNOSTICS MODALITIES
  • 8.3.1 IMMUNOASSAY
    • 8.3.1.1 Increasing focus on individualized therapies to drive market
  • 8.3.2 CLINICAL CHEMISTRY
    • 8.3.2.1 Increased demand for precision medicine and efficient healthcare systems to drive market
  • 8.3.3 HEMATOLOGY
    • 8.3.3.1 Rising need for efficient blood disorder diagnostics and advancements in AI-driven technologies to drive market
  • 8.3.4 MICROBIOLOGY
    • 8.3.4.1 Rising demand for precise diagnostics and antimicrobial resistance drives AI adoption
  • 8.3.5 OTHER DIAGNOSTIC MODALITIES

9 ARTIFICIAL INTELLIGENCE IN MEDICAL DIAGNOSTICS MARKET, BY APPLICATION

• 9.1 INTRODUCTION
• 9.2 IN VIVO DIAGNOSTICS APPLICATIONS
  • 9.2.1 RADIOLOGY
    • 9.2.1.1 Pressing need for accurate imaging interpretation and reduction of diagnostic errors to drive demand for AI
  • 9.2.2 ONCOLOGY
    • 9.2.2.1 Early cancer detection and personalized therapies to drive market
  • 9.2.3 CARDIOLOGY
    • 9.2.3.1 Rising complexities associated with CVD to drive market
  • 9.2.4 NEUROLOGY
    • 9.2.4.1 Application in diagnosing Alzheimer's to boost demand for AI technologies
  • 9.2.5 OBSTETRICS/GYNECOLOGY
    • 9.2.5.1 Rising use of minimally invasive techniques in gynecology procedures to drive market
  • 9.2.6 OPHTHALMOLOGY
    • 9.2.6.1 Rising need for early detection & prevention of eye diseases to drive market
  • 9.2.7 OTHER IN VIVO APPLICATIONS
• 9.3 IN VITRO DIAGNOSTICS APPLICATIONS
  • 9.3.1 INFECTIOUS DISEASES
    • 9.3.1.1 Need for disease outbreak management and antimicrobial resistance to drive market
  • 9.3.2 ENDOCRINOLOGY
    • 9.3.2.1 Rising use of AI for diagnosing diabetes and thyroid disorders to drive market
  • 9.3.3 AUTOIMMUNE TESTING
    • 9.3.3.1 Capability to enhance accuracy in detecting autoimmune diseases to improve early diagnosis and treatment to drive market
  • 9.3.4 BLOOD SCREENING AND COAGULATION TESTING
    • 9.3.4.1 Increasing demand for screening bloodborne diseases and coagulation disorders to drive market
  • 9.3.5 OTHER IN VITRO APPLICATIONS

10 ARTIFICIAL INTELLIGENCE IN MEDICAL DIAGNOSTICS MARKET, BY REGION

• 10.1 INTRODUCTION
• 10.2 NORTH AMERICA
  • 10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 10.2.2 US
    • 10.2.2.1 Increasing number of imaging procedures to drive market
  • 10.2.3 CANADA
    • 10.2.3.1 Research grants and improved academics in radiology to drive market
• 10.3 EUROPE
  • 10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 10.3.2 GERMANY
    • 10.3.2.1 Rising government support for promoting adoption of AI in medical diagnostics to drive market
  • 10.3.3 FRANCE
    • 10.3.3.1 Availability of funding for companies to enhance AI research in medical imaging to fuel market growth
  • 10.3.4 UK
    • 10.3.4.1 Increasing radiography procedures to drive market
  • 10.3.5 ITALY
    • 10.3.5.1 Increasing volume of EHRs and EMRs due to rising geriatric population to drive demand
  • 10.3.6 SPAIN
    • 10.3.6.1 Growing awareness regarding AI to favor market growth
  • 10.3.7 REST OF EUROPE
• 10.4 ASIA PACIFIC
  • 10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 10.4.2 CHINA
    • 10.4.2.1 Rising use of AI in clinical decision-making to drive market
  • 10.4.3 JAPAN
    • 10.4.3.1 Strong healthcare infrastructure to drive uptake of advanced AI solutions
  • 10.4.4 INDIA
    • 10.4.4.1 Favorable government initiatives for R&D investments to drive market
  • 10.4.5 REST OF ASIA PACIFIC
• 10.5 LATIN AMERICA
  • 10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 10.5.2 BRAZIL
    • 10.5.2.1 High technological advancements in healthcare market to drive market
  • 10.5.3 MEXICO
    • 10.5.3.1 Investment inflows and initiatives for AI-related education to drive market
  • 10.5.4 REST OF LATIN AMERICA
• 10.6 MIDDLE EAST & AFRICA
  • 10.6.1 GCC COUNTRIES
    • 10.6.1.1 Rising adoption of AI in diagnostics to elevate healthcare standards, streamline operations, and make high-quality care more available to drive market
  • 10.6.2 REST OF MIDDLE EAST & AFRICA

11 COMPETITIVE LANDSCAPE

• 11.1 OVERVIEW
• 11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
• 11.3 REVENUE ANALYSIS
• 11.4 MARKET SHARE ANALYSIS
• 11.5 RANKING ANALYSIS
• 11.6 COMPANY EVALUATION MATRIX: KEY PLAYERS 2023
  • 11.6.1 STARS
  • 11.6.2 EMERGING LEADERS
  • 11.6.3 PERVASIVE PLAYERS
  • 11.6.4 PARTICIPANTS
  • 11.6.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 11.6.5.1 Company footprint
    • 11.6.5.2 Component footprint
    • 11.6.5.3 Application footprint
    • 11.6.5.4 End user footprint
    • 11.6.5.5 Regional footprint
• 11.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 11.7.1 PROGRESSIVE COMPANIES
  • 11.7.2 DYNAMIC COMPANIES
  • 11.7.3 RESPONSIVE COMPANIES
  • 11.7.4 STARTING BLOCKS
  • 11.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
    • 11.7.5.1 Detailed list of key startups/SMEs
    • 11.7.5.2 Competitive benchmarking of key startups/SMEs
• 11.8 COMPANY VALUATION AND FINANCIAL METRICS
• 11.9 BRAND/PRODUCT COMPARISON
• 11.10 COMPETITIVE SCENARIO
  • 11.10.1 PRODUCT LAUNCHES
  • 11.10.2 DEALS
  • 11.10.3 OTHERS

12 COMPANY PROFILES

• 12.1 KEY PLAYERS
  • 12.1.1 MICROSOFT
    • 12.1.1.1 Business overview
    • 12.1.1.2 Products/Solutions/Services offered
    • 12.1.1.3 Recent developments
      • 12.1.1.3.1 Product launches
      • 12.1.1.3.2 Deals
    • 12.1.1.4 MnM view
      • 12.1.1.4.1 Key strengths/Right to win
      • 12.1.1.4.2 Strategic choices
      • 12.1.1.4.3 Weaknesses/Competitive threats
  • 12.1.2 NVIDIA CORPORATION
    • 12.1.2.1 Business overview
    • 12.1.2.2 Products/Solutions/Services offered
    • 12.1.2.3 Recent developments
      • 12.1.2.3.1 Product launches
    • 12.1.2.4 MnM view
      • 12.1.2.4.1 Key strengths/Right to win
      • 12.1.2.4.2 Strategic choices
      • 12.1.2.4.3 Weaknesses/Competitive threats
  • 12.1.3 MERATIVE
    • 12.1.3.1 Business overview
    • 12.1.3.2 Products/Solutions/Services offered
    • 12.1.3.3 Recent developments
      • 12.1.3.3.1 Product launches
      • 12.1.3.3.2 Deals
      • 12.1.3.3.3 Others
      • 12.1.3.3.4 Expansions
    • 12.1.3.4 MnM view
      • 12.1.3.4.1 Key strengths/Right to win
      • 12.1.3.4.2 Strategic choices
      • 12.1.3.4.3 Weaknesses/Competitive threats
  • 12.1.4 GOOGLE (ALPHABET, INC.)
    • 12.1.4.1 Business overview
    • 12.1.4.2 Products/Solutions/Services offered
    • 12.1.4.3 Recent developments
      • 12.1.4.3.1 Product launches
      • 12.1.4.3.2 Deals
      • 12.1.4.3.3 Others
    • 12.1.4.4 MnM view
      • 12.1.4.4.1 Key strengths/Right to win
      • 12.1.4.4.2 Strategic choices
      • 12.1.4.4.3 Weaknesses/Competitive threats
  • 12.1.5 INTEL CORPORATION
    • 12.1.5.1 Business overview
    • 12.1.5.2 Products/Solutions/Services offered
    • 12.1.5.3 Recent developments
      • 12.1.5.3.1 Product launches
      • 12.1.5.3.2 Deals
    • 12.1.5.4 MnM view
      • 12.1.5.4.1 Key strengths/Right to win
      • 12.1.5.4.2 Strategic choices
      • 12.1.5.4.3 Weaknesses/Competitive threats
  • 12.1.6 SIEMENS HEALTHINEERS AG
    • 12.1.6.1 Business overview
    • 12.1.6.2 Products/Solutions/Services offered
    • 12.1.6.3 Recent developments
      • 12.1.6.3.1 Product launches
      • 12.1.6.3.2 Deals
  • 12.1.7 GE HEALTHCARE
    • 12.1.7.1 Business overview
    • 12.1.7.2 Products/Solutions/Services offered
    • 12.1.7.3 Recent developments
      • 12.1.7.3.1 Product launches
      • 12.1.7.3.2 Deals
      • 12.1.7.3.3 Others
      • 12.1.7.3.4 Expansions
  • 12.1.8 ADVANCED MICRO DEVICES, INC.
    • 12.1.8.1 Business overview
    • 12.1.8.2 Products/Solutions/Services offered
    • 12.1.8.3 Recent developments
      • 12.1.8.3.1 Product launches
      • 12.1.8.3.2 Deals
  • 12.1.9 KONINKLIJKE PHILIPS N.V.
    • 12.1.9.1 Business overview
    • 12.1.9.2 Products/Solutions/Services offered
    • 12.1.9.3 Recent developments
      • 12.1.9.3.1 Product launches
      • 12.1.9.3.2 Deals
      • 12.1.9.3.3 Others
  • 12.1.10 DIGITAL DIAGNOSTICS, INC.
    • 12.1.10.1 Business overview
    • 12.1.10.2 Products/Solutions/Services offered
    • 12.1.10.3 Recent developments
      • 12.1.10.3.1 Deals
      • 12.1.10.3.2 Others
      • 12.1.10.3.3 Expansions
  • 12.1.11 INFORMAI
    • 12.1.11.1 Business overview
    • 12.1.11.2 Products/Solutions/Services offered
    • 12.1.11.3 Recent developments
      • 12.1.11.3.1 Deals
      • 12.1.11.3.2 Others
• 12.2 OTHER PLAYERS
  • 12.2.1 HEARTFLOW, INC.
  • 12.2.2 ENLITIC, INC.
  • 12.2.3 AIDENCE
  • 12.2.4 BUTTERFLY NETWORK, INC.
  • 12.2.5 NANO-X IMAGING LTD.
  • 12.2.6 VIZ.AI, INC.
  • 12.2.7 QUIBIM
  • 12.2.8 QURE.AI
  • 12.2.9 THERAPIXEL
  • 12.2.10 AIDOC
  • 12.2.11 LUNIT, INC.
  • 12.2.12 ECHONOUS, INC.
  • 12.2.13 ICOMETRIX
  • 12.2.14 BRAINOMIX

13 APPENDIX

• 13.1 DISCUSSION GUIDE
• 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 13.3 CUSTOMIZATION OPTIONS
• 13.4 RELATED REPORTS
• 13.5 AUTHOR DETAILS